Introduction
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease or motor neuron disease, is a devastating and rapidly progressing neurological disorder. It attacks motor neurons, the nerve cells in the brain and spinal cord that control voluntary muscle movement. This degeneration leads to muscle weakness, atrophy, and eventually paralysis. ALS is characterized by the involvement of both upper and lower motor neurons, making it a complex and challenging condition to manage. Respiratory failure is the most common cause of death, and the prognosis is generally poor, with a typical survival of two to five years from symptom onset. Current treatments are primarily focused on managing symptoms such as spasticity and speech difficulties, highlighting the urgent need for better understanding and therapeutic interventions for ALS.
The COVID-19 pandemic, beginning in late 2019, presented an unprecedented global health crisis. The rapid development and deployment of COVID-19 vaccines were crucial in mitigating the pandemic’s impact. Vaccines from Pfizer-BioNTech, Moderna, and Janssen/Johnson & Johnson (J&J) received emergency use authorization from the U.S. FDA and have been administered to billions worldwide. Large-scale clinical trials have confirmed the safety and efficacy of these vaccines for the majority of recipients. However, like all medical interventions, COVID-19 vaccines are associated with side effects. While most are mild and transient, such as headache and fatigue, more serious adverse events, including anaphylaxis, Guillain-Barré Syndrome (GBS), myocarditis, and immune thrombotic thrombocytopenia, have been reported. This article presents a case of a previously healthy man who developed symptoms consistent with ALS shortly after receiving the Janssen/Johnson & Johnson COVID-19 vaccine, prompting an important discussion about potential associations between COVID-19 vaccination and neurodegenerative conditions.
Case Report
A 47-year-old male presented to a clinic with a nine-month history of progressive left-sided weakness, speech difficulties, dysphagia, and recurrent falls. Remarkably, his symptoms began just one day after receiving the single-dose Janssen/J&J viral vector COVID-19 vaccine. Prior to vaccination, he was a highly active and healthy mail carrier, walking approximately 10 miles daily, with no functional impairments. His medical history included well-managed depression, anxiety, hypertension, and obesity. Of particular relevance was his family history, notable for diabetes, hypertension, and coronary artery disease in his mother, and importantly, amyotrophic lateral sclerosis (ALS) in his grandmother.
The patient reported initial painful inflammation at the vaccine injection site. Within a week, he developed noticeable left arm weakness and reduced hand grip strength. Over the subsequent months, his condition progressed significantly, encompassing weakness in his left upper and lower extremities, slurred speech, difficulty swallowing (dysphagia), and frequent falls. Extensive diagnostic imaging, including MRI of the brain and entire spine, revealed no significant abnormalities, other than age-related degenerative changes and minor left-sided foraminal narrowing at the C4–C5 and C5–C6 levels, which were not considered clinically significant for his presenting symptoms.
Neurological examination revealed several key findings. He exhibited fasciculations and atrophy in his left arm, along with spasticity and hyperreflexia. Pathological reflexes, Babinski’s sign and Hoffman’s sign, were present bilaterally. His speech was characterized by spastic dysarthria. He demonstrated sustained clonus at both ankles and a pseudobulbar affect, marked by emotional lability. Sensory function, coordination, and gait were otherwise intact. Routine laboratory blood tests were within normal limits.
Following referral to a neurologist and comprehensive electromyography studies, the patient received a diagnosis of ALS with pseudobulbar affect. He was started on riluzole, a medication used to slow the progression of ALS, and continued to receive outpatient neurological care.
Discussion
This case report describes the onset of ALS symptoms in a previously healthy 47-year-old male shortly after receiving the Janssen/J&J COVID-19 vaccine. While the patient had no pre-existing neurological conditions, he did have a significant family history of ALS, with his grandmother affected by the disease. This raises the critical question of a potential link, or at least temporal association, between COVID-19 vaccination and the development of ALS, particularly in individuals with genetic predispositions or other risk factors.
COVID-19 vaccines are undeniably a cornerstone of public health in combating the pandemic. However, a comprehensive understanding of their potential adverse effects is crucial. The Vaccine Adverse Event Reporting System (VAERS) in the United States serves as a vital surveillance tool for monitoring vaccine safety. A study analyzing VAERS data indicated that neurological adverse events constituted a notable proportion (33%) of reported adverse events following COVID-19 vaccination, although the overall incidence of adverse events remains low (0.10% of vaccine recipients). The majority of neurological symptoms reported were mild, such as headaches, dizziness, and fatigue, and were more frequently associated with the Janssen vaccine in some reports. However, serious neurological conditions like Guillain-Barré Syndrome, transverse myelitis, cerebral venous thrombosis, and acute disseminated encephalomyelitis have also been reported, albeit rarely. The same VAERS study noted a very weak statistical association between ALS and COVID-19 vaccines, with extremely low reported incidence rates for Pfizer, Moderna, and J&J vaccines (0.02, 0.01, and 0.00 cases per 1,000,000 doses, respectively). It is important to interpret VAERS data cautiously, as it relies on passive reporting and cannot establish causality.
A cumulative review of post-vaccination adverse events conducted by Pfizer, examining data from December 2020 to February 2021, analyzed 501 cases of neurologic adverse events of special interest (1.2% of total adverse events). These included serious conditions such as epilepsy, seizures, GBS, multiple sclerosis relapse, and optic neuritis. Notably, ALS was not among the neurological adverse events reported in this Pfizer review.
The underlying mechanism for a potential link between COVID-19 vaccination and ALS remains unclear and requires further investigation. One plausible hypothesis involves the vaccine-induced immune response. COVID-19 vaccines are designed to stimulate a robust immune response to protect against the virus. In susceptible individuals, this enhanced immune activation could potentially trigger neuroinflammation, a process implicated in the pathogenesis of neurodegenerative diseases, including ALS. Supporting this concept, a study reported rapid functional decline in two patients with pre-existing slow-progressing ALS following COVID-19 infection. The authors suggested that COVID-19 itself could accelerate neurodegeneration through neuroinflammatory mechanisms, implying that both the virus and the immune response could act as triggers.
The patient’s family history of ALS is a critical factor in this case. Genetic predisposition plays a significant role in ALS, and it is conceivable that the vaccine acted as an environmental trigger in a genetically susceptible individual, accelerating the onset of ALS. Further research is needed to identify potential risk factors and determine if specific patient populations, particularly those with a family history of neurodegenerative diseases, require modified vaccination strategies or heightened monitoring.
It is essential to acknowledge the limitations of this case report. The primary limitation is the temporal association between vaccination and ALS symptom onset. While symptoms began shortly after vaccination, temporal association does not prove causation. It is possible that the ALS diagnosis in this patient was coincidental and would have occurred regardless of vaccination. With billions of vaccine doses administered globally, the occurrence of rare adverse events and the diagnosis of neurodegenerative diseases in the vaccinated population are expected by chance alone. Therefore, rigorous scientific studies are necessary to determine if there is a causal relationship between COVID-19 vaccines and ALS or other neurodegenerative conditions.
Conclusion
This case report underscores several important points. Firstly, it highlights the critical need for ongoing and robust surveillance of adverse events following COVID-19 vaccination, particularly in individuals with pre-existing medical conditions or relevant family histories. Secondly, it emphasizes the importance of further research to investigate potential links between COVID-19 vaccines and the development or acceleration of neurodegenerative diseases like ALS. Such research should focus on elucidating potential mechanisms, identifying risk factors, and refining patient selection for vaccination. Finally, this case serves as a reminder of the necessity for continuous education and training for healthcare providers to remain informed about the evolving understanding of vaccine safety, guidelines, and best practices related to vaccine administration and monitoring. Further research and data are crucial to fully understand the complex interplay between COVID-19 vaccination and neurological health.
References
[1] Kiernan MC, Vucic S, Cheah SM, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955. doi:10.1016/S0140-6736(10)61156-7
[2] Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease. Cochrane Database Syst Rev. 2012;2012(3):CD001139. doi:10.1002/14651858.CD001139.pub3
[3] Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162-172. doi:10.1056/NEJMra1700774
[4] Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
[5] Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
[6] Sadoff J, Gray G, Vandebosch M, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2104845
[7] Stone CA Jr, Rukasin CR, Beachkofsky TM, et al. Immediate Hypersensitivity to mRNA COVID-19 Vaccines. J Allergy Clin Immunol Pract. 2021;9(2):568-581.e5. doi:10.1016/j.jaip.2020.12.002
[8] Lee SH, Choi J, Kim JY, et al. Neurological Complications Following COVID-19 Vaccination. J Korean Med Sci. 2021;36(48):e335. doi:10.3346/jkms.2021.36.e335
[9] Patone M, Mei HE, Dale KM, et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation. 2022;146(9):743-757. doi:10.1161/CIRCULATIONAHA.122.059970
[10] Sharifian-Dorche M, Huwaizi GN, Eftekharifar A, et al. Neurological complications of coronavirus disease 2019 (COVID-19) vaccination; a systematic review and meta-analysis. J Neurol. 2022;269(1):56-72. doi:10.1007/s00415-021-10664-5
[11] Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Verma A. COVID-19 vaccines and Guillain-Barré syndrome: rapid review and meta-analysis. Muscle Nerve. 2022;65(1):4-8. doi:10.1002/mus.27465
[12] Chen Y, Xu Z, Shi P, et al. Neurological adverse events following administration of COVID-19 vaccines: A disproportionality analysis using the Vaccine Adverse Event Reporting System (VAERS) database. Front Neurol. 2022;13:820396. doi:10.3389/fneur.2022.820396
[13] Pfizer. Cumulative Analysis of Post-authorization Adverse Event Reports of BNT162b2 Reported Through 28-Feb-2021. https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
[14] Filatov A, Sharma R, Hindi F, et al. Rapid Functional Decline in 2 Patients With Amyotrophic Lateral Sclerosis and COVID-19. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e814. doi:10.1212/NXI.0000000000000814
